Correction to: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x) / Sharman, J. P.; Egyed, M.; Jurczak, W.; Skarbnik, A.; Pagel, J. M.; Flinn, I. W.; Kamdar, M.; Munir, T.; Walewska, R.; Corbett, G.; Fogliatto, L. M.; Herishanu, Y.; Banerji, V.; Coutre, S.; Follows, G.; Walker, P.; Karlsson, K.; Ghia, P.; Janssens, A.; Cymbalista, F.; Woyach, J. A.; Ferrant, E.; Wierda, W. G.; Munugalavadla, V.; Yu, T.; Wang, M. H.; Byrd, J. C.. - In: LEUKEMIA. - ISSN 0887-6924. - 39:2(2024). [10.1038/s41375-024-02487-1]
Correction to: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia (Leukemia, (2022), 36, 4, (1171-1175), 10.1038/s41375-021-01485-x)
Ghia P.
;
2024-01-01
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
